This study aimed to investigate the long-term impacts of disclosing amyloid status for a risk of Alzheimer disease (AD) to cognitively normal research participants with subjective cognitive decline (SCD), which represents an initial manifestation of AD. Forty-two participants were classified as the amyloid-positive (n = 10) or amyloid-negative (n = 32) groups. We assessed symptoms of anxiety, depression, and test-related distress at 6, 24, and 52 weeks after results disclosure. No difference was found over time in anxiety, depression, and test-related distress in either group. Although no significant differences were observed between groups in anxiety or depression, the amyloid-negative group had a significantly higher level of test-related distress than the amyloid-positive group at 52 weeks. Disclosing amyloid status to cognitively healthy research participants with SCD did not cause significant long-term psychological risks. However, a theoretical spectrum of subjective concern may exist about cognitive decline in amyloid-negative individuals.

中文翻译：

---

对患有主观认知下降的认知正常研究参与者的阿尔茨海默氏病风险的淀粉样蛋白状态的披露：一项纵向研究。

这项研究的目的是调查因患有阿尔茨海默病（AD）的风险而暴露于淀粉样蛋白状态对具有主观认知下降（SCD）的认知正常研究参与者的长期影响，这代表了AD的最初表现。42名参与者分为淀粉样蛋白阳性（n = 10）或淀粉样蛋白阴性（n = 32）组。我们在结果披露后的第6、24和52周评估了焦虑，抑郁和与测试相关的困扰症状。两组的焦虑，抑郁和与测试相关的痛苦随着时间的推移均未发现差异。尽管两组之间在焦虑或抑郁方面没有观察到显着差异，但在52周时，淀粉样蛋白阴性组的测试相关困扰程度明显高于淀粉样蛋白阳性组。向患有SCD的认知健康研究参与者披露淀粉样蛋白状态不会引起重大的长期心理风险。但是，关于淀粉样蛋白阴性个体认知能力下降的主观关注理论范围可能存在。